With nuclear medicine and radiopharmaceuticals now being recognized around the world for their life-saving potential in fighting diseases such as cancer, the sector is anticipating significant growth, with the global market for nuclear medicine expected to reach $33 billion USD in the next ten years. Recognizing this growing market, there are many opportunities for (Canadian) start-ups and small companies to leverage and commercialize their technologies.
This webinar featured a panel of leaders from across the nuclear medicine, biomanufacturing and biopharmaceutical sectors who have successfully raised capital for their projects. These leaders highlighted the challenges associated with accessing risk-adverse capital in Canada, and discuss how industry, clinicians, and researchers can build more intentional relationships to tailor commercialization efforts to meet the needs of emerging projects, tracers, and studies.
The panel consists of:
Owen Roberts, CPDC/CMIE (Moderator)
Ghadeer Shubassi, AtomVie
Nicholas Calvert, Yellowbird Diagnostics
Bill Dickie, Pandora Pharmaceuticals
The CNIC has more interesting recordings available. You can find them here.